Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: To switch or to combine? A nationwide study in Hungary

Schizophrenia Research

Volumn 152, Issue 1, 2014, Pages 246-254

  Katona, Lajos ^a   Czobor, Pál ^b,c   Bitter, István ^c  

^a National Health Insurance Fund   (Hungary)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^c SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

All cause discontinuation; Antipsychotic; Combination; Hospitalization; Mortality; Polypharmacy; Schizophrenia; Switching

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG FORMULATION; DRUG WITHDRAWAL; FEMALE; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; HUNGARY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; OUTCOME ASSESSMENT; PARALLEL DESIGN; POLYPHARMACY; PRIORITY JOURNAL; PROPENSITY SCORE; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SCHIZOPHRENIA; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; DATA ANALYSIS; DRUG RESPONSE; MIDDLE AGED; SENSITIVITY ANALYSIS; SURVIVAL TIME; TREATMENT DURATION;

ALL-CAUSE DISCONTINUATION; ANTIPSYCHOTIC; COMBINATION; HOSPITALIZATION; MORTALITY; POLYPHARMACY; SCHIZOPHRENIA; SWITCHING;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; DRUG COMBINATIONS; DRUG SUBSTITUTION; FEMALE; HUMANS; HUNGARY; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; POLYPHARMACY; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 84891634194     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.10.034     Document Type: Article

References (41)

1. Ascher-Svanum H., Brnabic A.J., Lawson A.H., Kinon B.J., Stauffer V.L., Feldman P.D., Kelin K. Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia. Neuropsychiatr. Dis. Treat. 2012, 8:113-118.
2. Ballon J., Stroup T.S. Polypharmacy for schizophrenia. Curr. Opin. Psychiatry 2013, 26:208-213.
3. Barbui C., Signoretti A., Mule S., Boso M., Cipriani A. Does the addition of a second antipsychotic drug improve clozapine treatment?. Schizophr. Bull. 2009, 35:458-468.
4. Barnes T.R., Paton C. Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs 2011, 25:383-399.
5. Bitter I., Treuer T., Dyachkova Y., Martenyi F., McBride M., Ungvari G.S. Antipsychotic prescription patterns in outpatient settings: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Eur. Neuropsychopharmacol. 2008, 18:170-180.
6. Chen L., McCombs J.S., Park J. Duration of antipsychotic drug therapy in real-world practice: a comparison with CATIE trial results. Value Health 2008, 11:487-496.
7. Cipriani A., Boso M., Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst. Rev. 2009, CD006324.
8. Correll C.U., Rummel-Kluge C., Corves C., Kane J.M., Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr. Bull. 2009, 35:443-457.
9. Cox D.R. Regression models and lifetables. J. R. Stat. Soc. 1972, 34:187-220.
10. Essock S.M., Schooler N.R., Stroup T.S., McEvoy J.P., Rojas I., Jackson C., Covell N.H. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am. J. Psychiatry 2011, 168:702-708.
11. Faries D., Ascher-Svanum H., Zhu B., Correll C., Kane J. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 2005, 5:26.
12. Federal Coordinating Council Federal Coordinating Council for Comparative Effectiveness Research Report to the President and the Congress 2009, US Department of Health and Human Services.
13. Fleischhacker W.W., Uchida H. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int. J. Neuropsychopharmacol. 2012, 1-11.
14. Fleischhacker W.W., Hummer M., Kurz M., Kurzthaler I., Lieberman J.A., Pollack S., Safferman A.Z., Kane J.M. Clozapine dose in the United States and Europe: implications for therapeutic and adverse effects. J. Clin. Psychiatry 1994, 55(Suppl. B):78-81.
15. Food and Drug Administration Public Law 110-85: Food and Drug Administration Amendments Act of 2007 2007.
16. Freedman R. The choice of antipsychotic drugs for schizophrenia. N. Engl. J. Med. 2005, 353:1286-1288.
17. Hartung D.M., Zerzan J., Yamashita T., Tong S., Morden N.E., Libby A.M. Characteristics and trends of low-dose quetiapine use in two western state Medicaid programs. Pharmacoepi. and drug safety 2013, 10.1002/pds.3538.
18. Hochberg Y. A sharper Bonferroni procedure for multiple test of significance. Biometrika 1988, 75:800-802.
19. Honer W.G., Thornton A.E., Sherwood M., MacEwan G.W., Ehmann T.S., Williams R., Kopala L.C., Procyshyn R., Barr A.M. Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia. CNS Drugs 2007, 21:699-714.
20. Josiassen R.C., Joseph A., Kohegyi E., Stokes S., Dadvand M., Paing W.W., Shaughnessy R.A. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am. J. Psychiatry 2005, 162:130-136.
21. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I.P., Gheorghe M.D., Rybakowski J.K., Galderisi S., Libiger J., Hummer M., Dollfus S., Lopez-Ibor J.J., Hranov L.G., Gaebel W., Peuskens J., Lindefors N., Riecher-Rossler A., Grobbee D.E. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008, 371:1085-1097.
22. Kreyenbuhl J., Valenstein M., McCarthy J.F., Ganoczy D., Blow F.C. Long-term combination antipsychotic treatment in VA patients with schizophrenia. Schizophr. Res. 2006, 84:90-99.
23. Lehman A.F., Lieberman J.A., Dixon L.B., McGlashan T.H., Miller A.L., Perkins D.O., Kreyenbuhl J. Practice guideline for the treatment of patients with schizophrenia, second edition. Am. J. Psychiatry 2004, 161:1-56.
24. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353:1209-1223.
25. Lin C.H., Kuo C.C., Chou L.S., Chen Y.H., Chen C.C., Huang K.H., Lane H.Y. A randomized, double-blind comparison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia. J. Clin. Psychopharmacol. 2010, 30:518-525.
26. NICE Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (Update), Final Version (NICE Clinical Guideline 82) 2009, National Institute for Health and Clinical Excellence (NICE).
27. Norwegian Institute of Public Health Norwegian Institute of Public Health, ATC/DDD Index 2012 http://www.whocc.no/atc_ddd_index/.
28. Oosthuizen P., Emsley R., Jadri T.H., Keyter N. A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis. Int. J. Neuropsychopharmacol. 2004, 7:125-131.
29. R Development Core Team R: A Language and Environment for Statistical Computing 2009, R Foundation for Statistical Computing, Vienna, Austria.
30. Rosenheck R.A., Davis S., Covell N., Essock S., Swartz M., Stroup S., McEvoy J., Lieberman J. Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. Schizophr. Res. 2009, 107:22-29.
31. Rosenheck R.A., Krystal J.H., Lew R., Barnett P.G., Fiore L., Valley D., Thwin S.S., Vertrees J.E., Liang M.H. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N. Engl. J. Med. 2011, 364:842-851.
32. Rupnow M.F., Greenspan A., Gharabawi G.M., Kosik-Gonzalez C., Zhu Y., Stahl S.M. Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder. Curr. Med. Res. Opin. 2007, 23:2815-2822.
33. Sekhon J.S. Multivariate and propensity score matching software with automated balance optimization: the matching package for R. J. Stat. Softw. 2011, 42:1-52.
34. Stroup T.S., Lieberman J.A., McEvoy J.P., Swartz M.S., Davis S.M., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis C.E., Severe J., Hsiao J.K. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am. J. Psychiatry 2006, 163:611-622.
35. Tiihonen J., Wahlbeck K., Lonnqvist J., Klaukka T., Ioannidis J.P., Volavka J., Haukka J. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006, 333:224.
36. Tiihonen J., Lonnqvist J., Wahlbeck K., Klaukka T., Niskanen L., Tanskanen A., Haukka J. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009, 374:620-627.
37. Tiihonen J., Haukka J., Taylor M., Haddad P.M., Patel M.X., Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am. J. Psychiatry 2011, 168:603-609.
38. Tiihonen J., Suokas J.T., Suvisaari J.M., Haukka J., Korhonen P. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch. Gen. Psychiatry 2012, 69:476-483.
39. Tranulis C., Skalli L., Lalonde P., Nicole L., Stip E. Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature. Drug Saf. 2008, 31:7-20.
40. Treatment of schizophrenia Treatment of schizophrenia 1999. The expert consensus guideline series. J. Clin. Psychiatry 1999, 60:3-80. Suppl 11.
41. World Health Organization The ICD-10 classification of mental and behavioural disorders. Clinical Descriptions and Diagnostic Guidelines 1992, World Health Organization, Geneva.